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Abstract Cryptococcal meningitis is a rare entity among
immunocompetent hosts but, when it occurs, it is associated
with significant morbidity and mortality. Clinical presen-
tation as well as the course of the disease is usually subtle
and indolent with headache and altered mental status. The
authors present the case of a 59-year-old man, who sought
medical help with a 2-week history of headaches accom-
panied by nausea and visual and hearing disturbances. On
admission the patient was afebrile, presented visual and
hearing deficits and had a normal magnetic resonance
image of the brain. A lumbar puncture was performed and
microscopic examination of the cerebrospinal fluid
revealed yeasts that were identified as Cryptococcus spp.
and later, by means of molecular biology techniques, as
Cryptococcus neoformans, var. grubii. The patient was
treated with liposomal amphotericin B plus fluconazole for
28 weeks. At follow-up after 1 year the patient was
asymptomatic and received fluconazole 400 mg/day as
prophylactic therapy. The outcome of Cryptococcus
infections in immunocompetent hosts is reported to be poor
as a result of a delayed diagnosis and suboptimal initial
antifungal therapy. The influence of the normal immune
response is unclear.
1 Introduction
Cryptococcus spp. are important fungal pathogens world-
wide. Cryptococcal meningitis is the fourth most common
life-threatening opportunistic infection in individuals with
AIDS [1], but is rare among immunocompetent hosts [2, 5].
Cryptococcosis is a systemic mycosis associated with sig-
nificant morbidity and mortality [3]. Its course is invariably
fatal when left untreated [4]. Clinical presentation as well
as the course of the disease is usually subtle and indolent
with headache and altered mental status. The impact of the
normal immune response is unclear [4]. The most common
symptoms are headache and altered mental status, includ-
ing personality changes, confusion, lethargy, obtundation,
and coma [4]. Clinical suspicion is crucial because men-
ingeal signs may be lacking. A lumbar puncture with
microbiological examination of the cerebrospinal fluid
(CSF) is diagnostic. Cryptococcus neoformans is the pre-
valent causative agent in cryptococcal infections among
immunocompromised patients.
2 Case Report
A 59-year-old Brazilian man, living in Portugal for 8 years
and working as a construction painter, visited our hospital
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with complaints of a progressive pulsating frontal headache
accompanied by nausea and visual and hearing distur-
bances that had started 2 weeks earlier. Analgesics and
anti-inflammatory drugs brought no relief. He denied
having experienced fever, dyspnea, dysuria, diarrhea or any
other symptom. He had a history of hypertension for which
he never used medication.
On physical examination he had a blood pressure of
140/80 mm Hg and a regular pulse rate of 64 beats/min.
His body temperature was normal. His mucous membranes
were normal in colour, he was well hydrated and physical
examination of the heart and lungs was unremarkable. The
Glasgow coma score was 15, he presented with moderate
hypoacusia and his visual acuity was diminished bilater-
ally, with limited abduction of the left eye and a binocular
horizontal diplopia. There was no neck rigidity or any other
meningeal sign.
Initial hematologic and biochemical analysis were nor-
mal: hemoglobin 13.7 g/L, leukocytes 5 9 103/UL with
900 lymphocytes, platelets 188 9 103/lL, normal renal and
liver function tests, glucose 105 mg/dL and a C-reactive
protein level of 1.1 mg/L. A computed tomography scan of
the brain, with contrast, displayed no abnormalities. A
lumbar puncture was performed; the opening pressure was
greater than 50 mm H20 and examination of the CSF
revealed glucose 53 mg/dl, proteins 0.39 g/L and 13 cells.
Direct microscopic examination of the CSF, with India
ink preparation, showed yeasts that were identified as
Cryptococcus spp. (Figs. 1, 2). These yeasts grew very
slowly in culture and were subsequently classified as
C. neoformans, var. grubii by means of molecular biology
techniques, namely analysis of the D2 region of the fungal
genome.
To map the neurological deficits the patient underwent a
visual evoked potentials test, which showed that latency of
waves P100, determined after individual stimulus of both
eyes, was bilaterally substantially delayed. This finding was
indicative of a severe neuroaxonal dysfunction of the optic
pathway. The auditory evoked potentials test showed that
the auditory pathways had also been affected bilaterally.
Upper and lower limb evoked potentials proved normal.
Hearing tests showed a plain bilateral neurosensorial hyp-
oacusia. Visual campimetry disclosed an annular constric-
tion, with an increase in the right eye blind spot in
conjunction with a nasal constriction and increase in the left
eye blind spot. Blood cultures were negative as were the
serological assays for HIV, hepatitis B, hepatitis C and
syphilis. CD4 cell count was 50.1 % and CD8 cell count
was 15.8 %. Serum protein electrophoresis and immuno-
electrophoresis were normal. Autoantibodies and other
markers of systemic diseases were not encountered. Further
examinations that included a computed tomography scan of
the paranasal sinuses, a magnetic resonance imaging scan of
the brain and the lumbar-sacral region, as well as a cerebral
angio-magnetic resonance imaging did not show any
abnormality.
The initial treatment consisted of liposomal amphoteri-
cin B at a dose of 3 mg/kg per day, but symptoms
Fig. 1 Analysis of CSF at initial lumbar puncture showing
C. neoformans, var. grubii (week 1)
Fig. 2 Analysis of CSF at initial lumbar puncture showing
C. neoformans, var. grubii with a specific reagent for an improved
identification of the causative agent (week 1)
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persisted. As there was no clinical improvement, the dose
of liposomal amphotericin B was increased to 6 mg/kg per
day at week 4. At week 6, there was still no clinical or
microbiological improvement and therefore fluconazole
800 mg/day was added, after which symptoms slowly
improved. For symptomatic relief weekly therapeutic
lumbar punctures were needed. The opening pressure
remained increased and direct microbiological examination
of the CSF with India ink preparation continued to reveal
cryptococci, although they did not grow in culture. A total
of 26 lumbar punctures was performed.
After 24 weeks of antifungal treatment, microscopic
examination of the CSF showed no yeasts for the first time,
but the patient continued to complain of moderately reduced
visual acuity and severe hypoacusia. Liposomal amphoteri-
cin B was stopped at week 28 and he was finally discharged at
week 32 under maintenance therapy with fluconazole
800 mg/day. While still in hospital he developed mild renal
failure interpreted as secondary to liposomal amphotericin
B, which improved after stopping the drug.
After discharge it was necessary to perform five more
lumbar punctures. In the first two CSF samples occasional
yeasts were still found but the last three were negative,
although the opening pressure remained above the normal
level. In January 2011, the date of the last lumbar puncture,
he was asymptomatic under prophylactic therapy with
fluconazole 400 mg/day. He continues to be under close
surveillance and is seen at regular intervals at the Neurol-
ogy Day Care Unit.
3 Discussion and Conclusion
This case highlights the importance of paying attention to
clinical symptoms, even in the presence of initially negative
laboratory and radiological investigations. The outcome of
cases of Cryptococcus infection in immunocompetent hosts
reported in the literature are poor as a result of three factors:
a delayed diagnosis, suboptimal initial antifungal therapy
and the normal immune response (a massive inflammatory
process can cause havoc in a confined space such as the
skull, which may contribute to intracerebral hypertension
and increased disease severity) [3].
In this particular case, there was no detectable immu-
nodeficiency and the etiological agent was initially difficult
to classify. The characteristic image of C. neoformans
(Fig. 3) (http://phil.cdc.gov/phil/details.asp?pid=3771) is
quite different from the CSF image seen in our laboratory
(Figs. 1, 2). It was therefore necessary to apply innovative
supplemental diagnostic methods, in particular molecular
biology techniques to classify the fungus.
The use of higher doses of liposomal amphotericin B
and the combination with another antifungal agent were, in
spite of later reported in-vitro intermediate resistance to
fluconazole, essential to achieve success. Moreover, it
appeared necessary to prolong therapy with liposomal
amphotericin B. Probably because of the prolonged therapy
with high-dose amphotericin B, the patient developed renal
failure that normalized after the suspension of the drug.
Early institution of therapy improves the prognosis of
cryptococcosis. Amphotericin B in combination with flu-
cytosine is the treatment of choice [3]. However, the latter
drug is only available in Portugal on the basis of a case-
by-case import, which makes it difficult to obtain in a timely
manner. For this reason, this drug was not used as first-line
therapy. The choice of liposomal amphotericin B was made
because classic amphotericin B is no longer available in
Portugal. Amphotericin B (classic and liposomal) have a
poor penetration in the central nervous system, so an
increase in the drug dose is frequently needed. On the other
hand, fluconazole and flucytosine readily penetrate the
central nervous system [6].
Cryptococcus meningitis is uncommon in immuno-
competent hosts but it causes high mortality and long-term
morbidity and should be considered in the differential
diagnostic assessment of patients who complain of chronic
headaches [2].
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